Products manufactured at the new Vaughan facility will support research in areas including cancer, infectious disease, mental health, and environmental safety
New unit boosts innovation in liposomal delivery technologies with 8,500 MT capacity and export-ready production
The Ma’anshan site approval covers pastilles, oral liquids, and powders
The facility has been designed with a dual focus on efficiency and sustainability
Biocytogen will provide proprietary, fully human antibodies derived from its RenMice platform for evaluation in Merck’s antibody-conjugated LNP services
New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value
Now integrates with Abbott’s instinct sensor and approved for type 2 diabetes
Phase 1 has a total reactor capacity of 440 kL with 63 reactors
It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
